

PATENT
Attorney Docket No. PC25047A US

I hereby certify that this correspondence is being filed with the United States Patent and Trademark Office via facsimile to Examiner Chukwuma O. Nwaonicha, Group Art Unit 1621 at facsimile number (703) 872-9306 on this 18th day of February 2005.

By

Kelley D. Surprenant
(Signature of person mailing)

Kelley D. Surprenant

(Typed or printed name of person)

WFEE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Matthew F. Brown *et al.*

Serial No.: 10/687,380

Filed: October 16, 2003

Title: HETEROARYL-HEXANOIC ACID
AMIDE DERIVATIVES AS
IMMUNOMODULATORY
AGENTS

Group Art Unit: 1621

Examiner: Chukwuma O. Nwaonicha

RECEIVED
CENTRAL FAX CENTER

FEB 18 2005

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

VIA FACSIMILE: (703) 872-9306 (3 Pages)

1814

**TERMINAL DISCLAIMER TO OBVIATE
A DOUBLE PATENTING REJECTION**

Sir:

Petitioner, Pfizer, Inc., hereby states that it is the assignee of the entire right, title and interest in the instant application. Petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§154 to 156 and 173, of prior United States Patent No. 6,403,587, as presently shortened by any terminal disclaimer. Petitioner hereby agrees that any patent so granted on the instant application shall be enforceable only for and

10687380

161445

02/22/2005 CTH0952 00000001 161445

130.00 DA

01 FC:1614

during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, Petitioner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that the prior patent later: expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR § 1.321; has all claims canceled by a reexamination certificate; is reissued; or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

The undersigned (whose title is supplied below) is empowered to act on behalf of Petitioner. The present non-provisional application is assigned by virtue of an assignment of parent provisional application 60/422,574 from the named inventors to Pfizer, Inc., which was recorded with the USPTO on November 25, 2002, a copy of which can be found at reel 013529 frame 0889.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that

USSN 10/687,380
Terminal Disclaimer

Page 2 of 3

PATENT
Attorney Docket No. PC25047A US


such willful false statements may jeopardize the validity of the application or any patent issued thereon.

The Commissioner is hereby authorized by this paper to charge the required fee under 37 C.F.R. §§ 1.321(b)(4) and 1.20(d) to Deposit Account 16-445. The Commissioner is hereby authorized by this paper to charge any additional fees that may be required or credit any overpayment to Deposit Account 16-445.

16-1445
(see Nxt,
pg. for
corr. acct. No.)
det
02/22/05

Respectfully submitted,

Date: February 18, 2005


Christopher J. Verni
Attorney for Applicants
Reg. No. 48,322

Customer No. 28523
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 686-2032

Doc. #: 80322v1

USSN 10/687,380
Terminal Disclaimer

Page 3 of 3

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

**FEE TRANSMITTAL
for FY 2004**

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small status. See 37 CFR 1.27

Total Amount of Payment 770

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None☒ Deposit AccountDeposit Account Number 16-1445
Deposit Account Name Pfizer Inc

The Director is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	770
1002	340	2002	170	Design filing fee	
1003	530	2203	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Reissue filing fee	

Subtotal (1)s \$ 770

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Extra Claims		Fee from below		Fee Paid
Total Claims				
17	- 20** = 0	18	= 0	
Independent Claims	1 - 3 = 0	85	= 0	
Multiple Dependent		290	= 0	

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	**Reissue independent claims over original patent
1205	18	2205	9	**Reissue independent claims over original patent

(S) 0

**or number previously paid, if greater. For Reissues, see above

Complete if Known

Application Number	To Be Assigned
Filing Date	Herewith
First Named Inventor	Matth w F. Brown
Examiner Name	To Be Assigned
Art Unit	To Be Assigned
Attorney Docket No.	PC25047A

FEE CALCULATION (continued)

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late fee or oath	
1052	50	2052	25	Surcharge-late filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for Ex Parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	850	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Sheet	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	
Other Fee (specify)					
*Reduced by Basic Filing Fee Paid					
Subtotal (3)					(S) 0

(Complete if applicable)

SUBMITTED BY		Registration No.	30,695	Telephone	(860) 715-4271
Name (Printed/Type)	Raymond D. Thompson	(Attorney Agent)			
Signature	<i>Raymond D. Thompson</i>			10/16/03	

Warning: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

If you need assistance in completing the form, call 1-800-pto-9199 and select option 2.

EXPRESS MAIL NO. EL989324631US